Long-term safety and efficacy study of riliprubart in participants with CIDP

Trial Identifier: LTS17261
Sponsor: Sanofi
Start Date: April 2025
Primary Completion Date: October 2029
Study Completion Date: October 2029
Condition: Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CANADA, Quebec GATINEAU, Quebec, CANADA, J8Y 1W2
CANADA, Quebec QUEBEC CITY, Quebec, CANADA, G1E 7G9
CHILE, Reg Metropolitana de Santiago LO BARNECHEA, Reg Metropolitana de Santiago, CHILE, 7691236
CHILE, Reg Metropolitana de Santiago SANTIAGO, Reg Metropolitana de Santiago, CHILE, 8207257
CHINA BEIJING, CHINA, 100053
CHINA BEIJING, CHINA, 100034
CHINA CHENGDU, CHINA, 610072
CHINA FUZHOU, CHINA, 350001
CHINA SHANGHAI, CHINA, 200040
CHINA WUHAN, CHINA, 430030
CZECHIA BRNO, CZECHIA, 625 00
DENMARK AARHUS, DENMARK, 8200
FRANCE BORDEAUX, FRANCE, 33076
FRANCE LE KREMLIN-BICÊTRE, FRANCE, 94270
FRANCE MARSEILLE, FRANCE, 13885
FRANCE PARIS, FRANCE, 75651
GERMANY GÖTTINGEN, GERMANY, 37075
GERMANY TÜBINGEN, GERMANY, 72076
ITALY, Genova GENOA, Genova, ITALY, 16132
ITALY, Milano MILAN, Milano, ITALY, 20132
ITALY, Milano ROZZANO, Milano, ITALY, 20089
ITALY, Pavia PAVIA, Pavia, ITALY, 27100
ITALY, Pisa PISA, Pisa, ITALY, 56126
ITALY, Roma ROME, Roma, ITALY, 00168
KOREA, REPUBLIC OF, Seoul-teukbyeolsi SEOUL, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 02841
NETHERLANDS AMSTERDAM, NETHERLANDS, 1105 AZ
POLAND, Lubelskie LUBLIN, Lubelskie, POLAND, 20-954
SERBIA BELGRADE, SERBIA, 11000
SPAIN BARCELONA, SPAIN, 08041
SPAIN BARCELONA, SPAIN, 08035
SPAIN VALENCIA, SPAIN, 46026
SPAIN, Madrid MAJADAHONDA, Madrid, SPAIN, 28222
SWEDEN STOCKHOLM, SWEDEN, 113 65
UNITED STATES, Alabama HOMEWOOD, Alabama, UNITED STATES, 35209
UNITED STATES, Kansas KANSAS CITY, Kansas, UNITED STATES, 66160